Last reviewed · How we verify
Sulfamethoxazole Trimethoprim Combination
Sulfamethoxazole-trimethoprim is a fixed-dose combination antibiotic that inhibits bacterial folate synthesis by blocking dihydropteroate synthase and dihydrofolate reductase, respectively.
Sulfamethoxazole-trimethoprim is a fixed-dose combination antibiotic that inhibits bacterial folate synthesis by blocking dihydropteroate synthase and dihydrofolate reductase, respectively. Used for Urinary tract infections, Pneumocystis jirovecii pneumonia (PCP) prophylaxis and treatment, Bacterial infections (various gram-positive and gram-negative organisms).
At a glance
| Generic name | Sulfamethoxazole Trimethoprim Combination |
|---|---|
| Also known as | BACTRIM |
| Sponsor | Baylor Research Institute |
| Drug class | Sulfonamide-dihydrofolate reductase inhibitor combination |
| Target | Dihydropteroate synthase; Dihydrofolate reductase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Sulfamethoxazole is a sulfonamide that inhibits dihydropteroate synthase, preventing the formation of dihydrofolate. Trimethoprim inhibits dihydrofolate reductase, blocking the conversion of dihydrofolate to tetrahydrofolate. Together, they create a synergistic effect by sequentially blocking bacterial folate metabolism, which is essential for nucleotide synthesis and bacterial growth.
Approved indications
- Urinary tract infections
- Pneumocystis jirovecii pneumonia (PCP) prophylaxis and treatment
- Bacterial infections (various gram-positive and gram-negative organisms)
- Toxoplasmosis
Common side effects
- Rash
- Nausea
- Vomiting
- Diarrhea
- Hyperkalemia
- Stevens-Johnson syndrome
- Hepatotoxicity
- Hematologic abnormalities
Key clinical trials
- A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial) (PHASE2)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients (PHASE4)
- Comparative Efficacy of Antibiotics for Small Intestine Bacterial Overgrowth in Bangladeshi Children (PHASE2)
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (PHASE4)
- Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia (PHASE3)
- STaph Aureus Resistance-Treat Early and Repeat (STAR-TER) (PHASE2)
- Role of Prophylactic Postoperative Antibiotics in HoLEP (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: